Posterior Reversible Encephalopathy Syndrome Associated with COVID-19 in a Japanese Patient

Yaguchi, Hiroaki; Mito, Yasunori; Kodama, Fumihiro; Tajima, Yasutaka

doi:10.2169/internalmedicine.7384-21

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemorrhage Hydroxychloroquine, antivirals, cobicitstat Good outcome Doo et al 2021 [ 41 ] 37 a 64 0 N/A N/A N/A Seizures P-O lesions. Hemorrhage Hydroxychloroquine, antibiotics ASMs Good outcome Talluri et al 2021 [ 42 ] 38 a 70 0 5 HTN, CAD, asthma 160 Alterations of consciousness O lesions Monoclonal Abs None Death Yaguchi et al 2021 [ 43 ] 39 90 Female 3 HTN 160 Focal signs, seizures O lesions None ASMs N/A Perez et al 2020 [ 44 ] 40 a 24 Female 4 N/A N/A Focal signs, alterations of consciousness Asymmetric, P lesions Antivirals, hydroxychloroquine, monoclonal Abs, antibiotics None Neurological sequelae Sripadma et al 2020 [ 45 ] 41 a 25 Female 1 Post-partum ...…”

Section: Resultsmentioning

confidence: 99%

Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis

et al. 2023

View full text Add to dashboard Cite

During the SARS-CoV2 pandemic, several cases of Posterior Reversible Encephalopathy Syndrome (PRES) and of Reversible Cerebral Vasoconstriction Syndrome (RCVS) in COVID-19 patients have been reported, but the link between these syndromes and COVID-19 is unclear. We performed a systematic review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to evaluate whether SARS-CoV2 infection or the drugs used to treat it could be deemed potential risk factors for PRES or RCVS. We performed a literature search. We found 70 articles (60 on PRES and 10 on RCVS) concerning n = 105 patients (n = 85 with PRES, n = 20 with RCVS). We analyzed the clinical characteristics of the two populations separately, then performed an inferential analysis to search for other independent risk factors. We found fewer than usual PRES-related (43.9%) and RCVS-related (45%) risk factors in patients with COVID-19. Such a low incidence of risk factors for PRES and RCVS might suggest the involvement of COVID-19 as an additional risk factor for both diseases due to its capability to cause endothelial dysfunction. We discuss the putative mechanisms of endothelial damage by SARS-CoV2 and antiviral drugs which may underlie the development of PRES and RCVS.

show abstract